Fazadinium Free Base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 414196

CAS#: 36653-54-0 (free base)

Description: Fazadinium Free Base is a rapid-acting, short-lasting, competitive nondepolarizing neuromuscular blocking agent; its action is rapidly and completely reversed by neostigmine.

Chemical Structure

img
Fazadinium Free Base
CAS# 36653-54-0 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 414196
Name: Fazadinium Free Base
CAS#: 36653-54-0 (free base)
Chemical Formula: C28H24N62+
Exact Mass: 444.21
Molecular Weight: 444.540
Elemental Analysis: C, 75.65; H, 5.44; N, 18.91

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 36653-54-0 (free base)   49564-56-9 (Br)  

Synonym: Fazadinium Free Base; Dazopironium

IUPAC/Chemical Name: Imidazo(1,2-a)pyridinium, 1,1'-azobis(3-methyl-2-phenyl-

InChi Key: NJAGGYXZTILBMJ-QVIHXGFCSA-N

InChi Code: InChI=1S/C28H24N6/c1-21-27(23-13-5-3-6-14-23)33(25-17-9-11-19-31(21)25)29-30-34-26-18-10-12-20-32(26)22(2)28(34)24-15-7-4-8-16-24/h3-20H,1-2H3/q+2/b30-29+

SMILES Code: Cc1c(c2ccccc2)n(\N=N\n3c(c(C)[n+]4ccccc34)c5ccccc5)c6cccc[n+]16

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 444.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Esener Z. The use of fazadinium in children. An electromyographic study. Br J Anaesth. 1983 Dec;55(12):1205-12. doi: 10.1093/bja/55.12.1205. PMID: 6140023.

2: Hartley JM, Fidler K. Rapid intubation with fazadinium. A comparison of fazadinium with suxamethonium and alcuronium. Anaesthesia. 1977 Jan;32(1):14-20. doi: 10.1111/j.1365-2044.1977.tb11551.x. PMID: 15467.

3: Bevan DR, D'Souza J, Rouse JM, Caldwell J, Smith RL. Clinical pharmacokinetics of fazadinium. Anaesthesia. 1980 Sep;35(9):873-8. doi: 10.1111/j.1365-2044.1980.tb03946.x. PMID: 6108730.

4: d'Hollander AA, Duvaldestin P, Delcroix C, Nevelsteen M, Desmonts JM. Evolution of single twitch and train-of-four responses and of tetanic fade in relation to plasma concentrations of fazadinium in man. Anesth Analg. 1982 Mar;61(3):225-30. PMID: 6121521.

5: Blackburn CL, Morgan M. Comparison of speed of onset of fazadinium, pancuronium, tubocurarine and suxamethonium. Br J Anaesth. 1978 Apr;50(4):361-4. doi: 10.1093/bja/50.4.361. PMID: 26369.

6: Hughes R, Payne JP, Sugai N. Studies on fazadinium bromide (ah 8165): a new non-depolarizing neuromuscular blocking agent. Can Anaesth Soc J. 1976 Jan;23(1):36-47. doi: 10.1007/BF03004993. PMID: 2378.

7: Kienlen J, du Callar J. Pharmacologie du fazadinium (AH 8165) [Pharmacology of fazadinium (AH 8165)]. Ann Anesthesiol Fr. 1981;22(6):631-9. French. PMID: 6124193.

8: Rainaldi MP, Busi T, Melloni C, Boschi S. Pharmacokinetics and placental transmission of fazadinium in elective caesarean sections. Acta Anaesthesiol Scand. 1984 Apr;28(2):222-5. doi: 10.1111/j.1399-6576.1984.tb02047.x. PMID: 6145279.

9: Hull CJ, English MJ, Sibbald A. Fazadinium and pancuronium: a pharmacodynamic study. Br J Anaesth. 1980 Dec;52(12):1209-21. doi: 10.1093/bja/52.12.1209. PMID: 6108777.

10: d'Hollander AA, Duvaldestin P, Henzel D, Delcroix C, Desmonts JM. Relationship between decay of plasma concentration of fazadinium and recovery from its neuromuscular blocking effect. Br J Anaesth. 1981 Aug;53(8):853-8. doi: 10.1093/bja/53.8.853. PMID: 6115662.